Observational study of inclisiran effectiveness in Moscow healthcare

QR Code

Observational study of inclisiran effectiveness in Moscow healthcare

Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 202...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. Yu. Vasilyeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2023-12-01
Series:	Российский кардиологический журнал
Subjects:	atherosclerosis inclisiran pcsk9 inhibitors
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5687
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2)
by: A. A. Avagimyan, et al.
Published: (2025-07-01)

Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
by: A. I. Sapina, et al.
Published: (2025-01-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

Comparative effectiveness of different methods of prescribing rosuvastatin and ezetimibe in combination with PCSK9 inhibitors
by: A. A. Kuznetsov, et al.
Published: (2024-06-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin
by: Fei Li, et al.
Published: (2025-07-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
by: E. A. Medvedeva, et al.
Published: (2023-05-01)

Features of lipid-lowering therapy in liver transplant recipients
by: A. A. Kucherov, et al.
Published: (2023-12-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
by: M. G. Bubnova
Published: (2018-07-01)

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
by: Wang Liang, et al.
Published: (2025-01-01)

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk
by: Mateusz Maligłówka, et al.
Published: (2025-06-01)

СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
by: С. С. Бажан
Published: (2013-12-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01)

ASSOTIATION OF THE GENETIC POLYMORPHISM E670G OF THE PCSK-9 AND THE SEVERITY OF THE CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN UZBEK POPULATION
by: R. B. Alieva, et al.
Published: (2019-09-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022-01-01)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023-04-01)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
by: Yu. A. Karpov
Published: (2019-01-01)

New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist
by: A. B. Skiba, et al.
Published: (2023-12-01)

First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation
by: M. A. Simonenko, et al.
Published: (2024-02-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

CORRECTION OF DYSLIPIDEMIA: HISTORICAL ASPECT AND CURRENT VIEW OF THE PROBLEM (REVIEW, PART IІ)
by: Dmytro D. Diachuk, et al.
Published: (2025-04-01)

Effect of combined lipid-lowering therapy on atherosclerotic plaque vulnerability in patients with acute coronary syndrome (Combi-LLT ACS): randomized trial protocol
by: A. N. Kovalskaya, et al.
Published: (2022-12-01)

Statin Intolerance and Adverse Effects in Lipid-Lowering Therapy – Pathomechanisms, Management Strategies, and Alternative Treatment Approaches
by: Natalia Śliwa, et al.
Published: (2025-06-01)

Insights into Binding Mechanisms of Potential Inhibitors Targeting PCSK9 Protein via Molecular Dynamics Simulation and Free Energy Calculation
by: Xingyu Wu, et al.
Published: (2025-07-01)

Does vitamin D supplementation benefit, harm, or have no effects on pregnant women or their babies?
by: article Editorial
Published: (2024-10-01)

THE INFLUENCE OF HYPOLIPIDEMIC THERAPY ON THE LEVEL OF MODIFIED LOW DENSITY LIPOPROTEIDES
by: V. Z. Lankin, et al.
Published: (2018-09-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

Genetic aspects of decreased low-density lipoprotein cholesterol values
by: A. N. Meshkov, et al.
Published: (2023-12-01)